Understanding the epidemiology and natural history of unrecognized Ebola virus infection
Understanding the epidemiology and natural history of unrecognized Ebola virus infection
批准号:
9806757
负责人:
John Daniel Kelly
金额:
$19.91万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-01 至 2023-07-31
关键词:
AddressAfricanAnimalsAntibodiesAntibody ResponseAreaBiometryBlindnessCaringClinicalComprehensive Health CareCounselingData AnalysesData CollectionDetectionDevelopmentDiagnosisDiseaseDisease OutbreaksEbola Hemorrhagic FeverEbola virusEmerging Communicable DiseasesEnrollmentEpidemiologyExposure toFilovirusFollow-Up StudiesFrankfurt-Marburg Syndrome VirusFutureGlycoproteinsHealth care facilityHealthcareImmunoglobulin GIndividualInfectionInflammatory ResponseInternationalLeadLiberiaLinkLongitudinal StudiesLongitudinal cohortLow PrevalenceMental DepressionMental HealthMentored Patient-Oriented Research Career Development AwardMentorsMonkeypoxNational Institute of Allergy and Infectious DiseaseNatural HistoryObservational StudyOutcomePatientsPoliciesPopulationPopulation SizesPrevalencePublic HealthPublishingQuality of lifeRecording of previous eventsReportingResearchResolutionResourcesRiskSerologic testsSerologicalServicesSurvivorsSymptomsUveitisViralViral Hemorrhagic FeversVirusVirus DiseasesWorkWorld Health Organizationanxiety symptomsbasecareer developmentclinical carecohortdata managementdepressive symptomsdesigndisabilityimprovedprogramspsychosocialrecruitseropositiveskillstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
A large number of Ebola virus infections may have been unrecognized during the 2013-2016 West
African outbreak, both undiagnosed Ebola virus disease (EVD) as well as mildly symptomatic and
asymptomatic infection. The epidemiology and natural history of infection in this unrecognized population,
which is defined by positive Ebola serology and a history of exposure, are poorly understood. For instance, it is
unknown if individuals with unrecognized infection have similar clinical and psychosocial sequelae as
recognized cases, such as uveitis, depression, and work-related disability. Understanding the extent to which
post-infectious sequelae occur and the predictors of unrecognized infection will bolster efforts to screen and
link unrecognized, infected individuals - both symptomatic and asymptomatic - to survivor services and to
better identify this population in future outbreaks.
I will study a well characterized cohort of individuals with serological evidence of past, unrecognized,
Ebola virus infection. I will utilize an existing cohort of close contacts of EVD survivors developed by the
National Institute of Allergy and Infectious Diseases' Partnership for Research on Ebola Virus in Liberia
(PREVAIL). The PREVAIL program began a natural history study of EVD survivors and their close contacts in
June 2015. Over 1,100 EVD survivors have been enrolled with the aim of characterizing their post-EVD clinical
sequelae, viral persistence, and durability of antibody response. Over 2,300 close contacts have also been
enrolled as the comparison population. A total of 230 (10%) close contacts of EVD survivors were found to be
seropositive by the quantitative FANG Ebola EIA and had not been reported as having had EVD. At study
baseline, 57% of this population reported having had symptoms in the three-week period after exposure to
Ebola virus, and 43% did not. This will be the first systematic, longitudinal study of unrecognized survivors of
Ebola virus infection.
This K23 proposal aims to: (1) identify the clinical sequelae of unrecognized, symptomatic Ebola virus
infection, (2) identify the predictors and clinical sequelae of unrecognized, asymptomatic Ebola virus infection,
and (3) identify psychosocial sequelae among unrecognized, symptomatic EVD survivors. My career
development aims involve: (1) design of observational studies, (2) advanced biostatistics, and (3) field
epidemiology in low-resource settings. This plan will be carried out with coursework, directed study, and the
guidance of an international team of mentors. In addition to future study of longer-term sequelae of EVD, I will
apply these skills and expertise to an R01 application in which I study the epidemiology and natural history of
other viral hemorrhagic fever and emerging infectious diseases such as Marburg virus and monkeypox.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VAccine failure: natural history and determinants of post-vaccination Covid-19
-
批准号:10595580
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:John Daniel Kelly
-
依托单位:
VAccine failure: natural history and determinants of post-vaccination Covid-19
-
批准号:10368287
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:John Daniel Kelly
-
依托单位:
Understanding the epidemiology and natural history of unrecognized Ebola virus infection
-
批准号:9981623
-
项目类别:
-
资助金额:$19.91万
-
财政年份:2019
-
负责人:John Daniel Kelly
-
依托单位:
Understanding the epidemiology and natural history of unrecognized Ebola virus infection
-
批准号:10224704
-
项目类别:
-
资助金额:$19.91万
-
财政年份:2019
-
负责人:John Daniel Kelly
-
依托单位:
Understanding the epidemiology and natural history of unrecognized Ebola virus infection
-
批准号:10456047
-
项目类别:
-
资助金额:$15.07万
-
财政年份:2019
-
负责人:John Daniel Kelly
-
依托单位:
海外基金